Evidence map›Paper›PMID 35245084›Full record

ArticleJCO global oncology2022

HOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America.

Carolina Bernabe-Ramirez, Ana I Velazquez, Coral Olazagasti, Cristiane Decat Bergerot, Paulo Gustavo Bergerot, Jose Corona Cruz, Ivy Riano, Christina Adaniel, Francisca Ramirez, Jesus Anampa and 21 more

Abstract read
In one paragraph

Article in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Time toxicity among older patients with cancer treated with palliative systemic therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Carolina Bernabe-RamirezEssen Health Care, Bronx, NY.ORCID 0000-0002-3312-3715
Ana I VelazquezDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA.ORCID 0000-0002-6153-5557
Coral OlazagastiSylvester Comprehensive Cancer Center at the University of Miami, Miami, ML.ORCID 0000-0002-6658-0170
Cristiane Decat BergerotCentro de Câncer de Brasília (CETTRO), Brasília, DF, Brazil.ORCID 0000-0003-0037-0303
Paulo Gustavo BergerotCentro de Câncer de Brasília (CETTRO), Brasília, DF, Brazil.ORCID 0000-0001-5770-324X
Jose Corona CruzInstituto Nacional de Cancerologia (INCan), Mexico City, Mexico.ORCID 0000-0001-5887-8834
Ivy RianoHematology and Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH.ORCID 0000-0002-3312-286X
Christina AdanielClinica Alemana, Santiago, Chile.ORCID 0000-0002-1771-4013
Francisca RamirezSOLCA, Instituto Oncologico Nacional, Guayaquil, Ecuador.
Jesus AnampaMontefiore Medical Center/Albert Einstein College of Medicine/Albert Einstein Cancer Center, Bronx, NY.ORCID 0000-0002-1898-180X
Carmen CajinaUniversidad Nacional Autonoma de Nicaragua, Managua, Nicaragua.
Evelin MenaInstituto Nacional Del Cancer Rosa Emilia Sanchez Perez de Tavares (INCART), Santo Domingo, Dominican Republic.
Elias GraciaNational Institute of Oncology and Radiobiology, Havana City, Cuba.ORCID 0000-0002-9389-9291
Alvaro MenendezHartford Healthcare, Hartford, CT.
Henry IdrovoUniversidad del Valle, Cali, Colombia.ORCID 0000-0002-7686-5874
Raimundo BezaresHospital Teodoro Alvarez Caba, Buenos Aires, Argentina.
Omar Orlando Castillo FernandezInstituto Oncologico Nacional, Panama City, Panama.ORCID 0000-0002-7038-974X
Liseth DuqueHospital Universitario Dr Jose Maria Vargas, Caracas, Venezuela.
Luis Corrales-RodríguezClinical Oncology Department, Hospital San Juan de Dios, San José, Costa Rica.ORCID 0000-0001-9732-5693
Glenda RamosSOLCA, Instituto Oncologico Nacional, Guayaquil, Ecuador.
Alba J Kihn-AlarcónResearch Department, Liga Nacional Contra el Cáncer & Instituto de Cancerología, Guatemala City, Guatemala.ORCID 0000-0003-4431-5998
Ilana SchlamTufts Medical Center, Boston, MA.ORCID 0000-0003-4996-0400
Ximena BrunoHematology Oncology Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-8461-387X
Gerardo UmanzorCentro Oncologico Integral in San Pedro Sula, Honduras.ORCID 0000-0002-0298-706X
Jenny Lissette CastroDepartment of Medical Oncology, Oncology Hospital, Salvadoran Institute of Social Security, Rosales National Hospital, San Salvador, El Salvador.
Federico LoscoInstituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina.
Luis UbillosHospital de Clínicas, Montevideo, Uruguay.ORCID 0000-0002-9081-7545
Eduardo RichardetInstituto Oncológico De Córdoba, Córdoba, Argentina.
Enrique Soto-Perez-de-CelisDepartment of Geriatrics, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.ORCID 0000-0002-7301-2163
Narjust DumaLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-7814-1773
HOLA COVID-19 Study Group

Funding

RESOURCE CENTER FOR AGING RESEARCH IN DIVERSE POPULATIONP30AG015272 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nynikka Palmer · 1997 to 2026
$19.5M
NIA NIH HHS P30 AG015272
6 · The paper itself

Abstract

purposeThe HOLA COVID-19 study sought to evaluate the impact of COVID-19 on oncology practices across Latin America (LATAM), challenges faced by physicians, and how practices and physicians adapted while delivering care to patients with cancer.

methodsThis international cross-sectional study of oncology physicians in LATAM included a 43-item anonymous online survey to evaluate changes and adaptations to clinical practice. Multivariable logistic regression analyses were used to evaluate the association of caring for patients with COVID-19 and changes to clinical practice.

resultsA total of 704 oncology physicians from 19 countries completed the survey. Among respondents, the most common specialty was general oncology (34%) and 56% of physicians had cared for patients with COVID-19. The majority of physicians (70%) noted a decrease in the number of new patients evaluated during the COVID-19 pandemic when compared with prepandemic, and 73% reported adopting the use of telemedicine in their practice. More than half (58%) of physicians reported making changes to the treatments that they offered to patients with cancer. In adjusted models, physicians who had cared for patients with COVID-19 had higher odds of changing the type of chemotherapy or treatments that they offered (adjusted odds ratio 1.81; 95% CI, 1.30 to 2.53) and of delaying chemotherapy start (adjusted odds ratio 2.05; 95% CI, 1.49 to 2.81). Physicians identified significant delays in access to radiation and surgical services, diagnostic tests, and supportive care.

conclusionThe COVID-19 pandemic has significantly disrupted global cancer care. Although changes to health care delivery are a necessary response to this global crisis, our study highlights the significant disruption and changes to the treatment plans of patients with cancer in LATAM resulting from the COVID-19 health care crisis.

Indexed as

COVID-19NeoplasmsCross-Sectional StudiesDelivery of Health CareHumansLatin AmericaPandemicsPatient CareSARS-CoV-2

Identifiers

PMID35245084
PMCPMC8920462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.